Prostate Cancer and Prostatic Diseases

Article	Citations
In regard to Boeri et al. ‘Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience’	129
Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes—ready for prime time?	91
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	74
Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study	53
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer	51
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	49
When precision meets prostate cancer: the rising role of HIFU focal therapy	45
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	45
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer	42
The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature	41
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	36
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	35
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis	35
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	32
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	31
Usefulness of podcasts to provide public education on prostate cancer genetics	30
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer	30
Goodbye and thanks for the memories	30
Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer	28
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications	27
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	27
Can there be consensus on whether vasectomy is a prostate cancer risk factor?	26
Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis	25
Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England	25
Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis	24

Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study	23
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN	23
Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number	23
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	23
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	23
Prostate cancer metastasis and health disparities: a systematic review	22
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	21
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries	21
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function	21
Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis	21
Prostate cancer genetic propensity risk score may modify the association between this tumour and type 2 diabetes mellitus (MCC-Spain study)	21
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	21
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series	20
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	20
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis	20
Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression	19
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	19
Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	19
Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?	19
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415	19
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	19
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis	19
More evidence that physical activity is beneficial for prostate cancer	19
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	18
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	18
Radical prostatectomy without prostate biopsy based on a noninvasive diagnostic strategy: a prospective single-center study	17
Nomograms in PCa: where do we stand	17
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer	16
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	16
The association between occupational asbestos exposure with the risk of incidence and mortality from prostate cancer: a systematic review and meta-analysis	16
The impact of race on survival in metastatic prostate cancer: a systematic literature review	16
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	16
Artificial intelligence applications in prostate cancer	15
Best of 2022 in prostate cancer and prostatic diseases	15
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials	15
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	15
EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy	15
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones	15
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	15
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	15
Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study	15
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	14
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	14
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	14
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	14
The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement	14
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative	14
Variation in communication of side effects in prostate cancer treatment consultations	14
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection	14
Impact of diverticular disease on prostate cancer risk among hypertensive men	14

Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled cli	14
Concerns regarding prostate cancer screening guidelines in minority populations	14
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	14
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer	14
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sens	13
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	13
Comparison of perioperative and short-terms outcomes of en-bloc Holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy: a propensity-score matching analysis	13
Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients	13
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	13
Clinicogenomic characterization of prostate cancer liver metastases	13
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases	13
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007–2022	13
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	13
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	12
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	12
Correction: Public interest in dietary supplements for prostate cancer prevention	12
Correction to: Advances in PSMA-targeted therapy for prostate cancer	12
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial	12
Statins and prostate cancer—hype or hope? The epidemiological perspective	12
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer	12
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	12
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	12
Germline alterations among Hispanic men with prostate cancer	12
Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction	12
Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	11
18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review	11
Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC)	11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	11
The evolving standards of active surveillance monitoring	11
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	11
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	11
Focal therapy for prostate cancer—ready to be a standard of care?	11
Comparison of senhance and da vinci robotic radical prostatectomy: short-term outcomes, learning curve, and cost analysis	11
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	11
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	11
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study	11
Association between genetic variations at 8q24 and prostate cancer risk in Mexican Men	11
Radiotheranostics in advanced prostate cancer: Current and future directions	10
Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation	10
Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020	10
MyProstateScore in men considering repeat biopsy: validation of a simple testing approach	10
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate	10
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	10
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	10
Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience	10
RE: “Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?”	10
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing	10
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	10
Hyperglycemia and microRNAs in prostate cancer	10
Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy	10
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers	10
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	9
The role of COVID-19 in prostate tissue inflammation: first pathological evidence	9
Length of positive surgical margins after radical prostatectomy: Does size matter? – A systematic review and meta-analysis	9
Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial	9
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men	9
Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?	9
Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis	9
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	9
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	9
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	9
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	9
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	9
Prostate cancer in New York City: impact of neighborhood level social determinants of care	9
Hospital volume and outcomes after radical prostatectomy: a national population-based study using patient-reported urinary continence and sexual function	9
Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	9
A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy	9
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate	8
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	8
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	8
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis	8
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	8
Developers-Doctor-patients: the artificial intelligence’s trifecta	8
The diagnostic yield of the Meares & Stamey test can be significantly improved by symptom-based patient selection and the experience of the test performer	8
From BPH to male LUTS: a 20-year journey of the EAU guidelines	8
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	8
The microbiome and prostate cancer	8
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	8
Statins and prostate cancer—hype or hope? The biological perspective	8

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry	8
Best of 2023 in Prostate Cancer and Prostatic Diseases	8
Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis	8
LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations	8
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	8
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer	8
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer	8
The natural history of a delayed detectable PSA after radical prostatectomy	8
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	8
TRexit is going one step further	7
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	7
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	7
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis	7
Quality of information and appropriateness of ChatGPT outputs for urology patients	7
Patient- and tumor-level risk factors for MRI-invisible prostate cancer	7
Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression	7
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs	7
Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review	7
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	7
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	7
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	7
Integrating risk calculators into routine clinical workflow for the detection of prostate cancer: next steps to achieve widespread adoption	7
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?	7
Incidence of prostate cancer in transgender women in the US: a large database analysis	7
The changing face of castrate resistant prostate cancer	7
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis	7
Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	6
Single-port transvesical simple prostatectomy for the surgical treatment of benign prostatic hyperplasia: functional and continence outcomes	6
“Quality: a parallel priority to quantity in prostate cancer focal therapy”	6
Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis	6
Correction: Germline alterations among Hispanic men with prostate cancer	6
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	6
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	6
Antimicrobial prophylaxis: To do or not to do? This is the question	6
Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer	6
One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia	6
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	6
Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review	6
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	6
Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial	6
The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)	6
The times have changed. Let the urologists change!	6
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy	6
Correction: Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	6
Setting new standards: robot-assisted radical prostatectomy as a day case	6
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study	6
Exercise impacts the epigenome of cancer	6
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120	6
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	6
Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy	6
Body weight, fat mass and metabolic complications during androgen deprivation therapy: should urologists recommend exercise and diet to help patients overcome toxicities?	6
Biopsy strategies in the era of mpMRI: a comprehensive review	6
Prostate cancer and prostatic diseases is “Your” journal	6
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)	5
High-intensity interval training versus moderate-intensity continuous training for localized prostate cancer under active surveillance: a systematic review and network meta-analysis	5
Should LHRH therapy be continued in patients receiving abiraterone acetate?	5
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study	5
Functional and oncological outcomes after radical prostatectomy in patients with history of surgery for lower urinary tract symptoms related to benign prostatic enlargement: A systematic review with m	5
From BPH to male LUTS: a 20-year journey of the EAU guidelines	5
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer	5
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth	5
Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States	5
Racial disparities in prostate cancer among black men: epidemiology and outcomes	5
Instagram and prostate cancer: using validated instruments to assess the quality of information on social media	5
Prostate cancer in low- and middle-income countries - challenges and opportunities	5
Psychological interventions in prostate cancer: a farewell to mind–body dualism	5
Allopurinol and prostate cancer survival in a Finnish population-based cohort	5
Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database	5
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?	5
Quality of information and appropriateness of Open AI outputs for prostate cancer	5
The evolving clinical use of prostate cancer biomarkers	5
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients	5
The spectrum of neuroendocrine differentiation in prostate cancer	5
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	5
Exercise medicine in men with prostate cancer: breaking barriers to increase participation	5
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control	5
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	5
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population	5
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	5
Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era	5
Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study	5
Importance of radiotherapy to the primary in metastatic hormone sensitive prostate cancer	5
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	5
Clinical considerations for the management of androgen indifferent prostate cancer	5
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer	5
Salvage treatments after focal therapy for prostate cancer – a comprehensive review	5
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	4
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer	4
Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy	4
Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study	4
Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis	4
PSA response to antiandrogen withdrawal: a systematic review and meta-analysis	4
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients	4
Androgen deprivation therapy and cognitive decline—associations with brain connectomes, endocrine status, and risk genotypes	4
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT	4